anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIM: There is currently no protocol for classifying patients with HPV persistence and preoperative stenosis of the cervical canal. This has a significant impact on cytology results, colposcopy results and the possibility of obtaining reliable cervical histology outcomes. Our analysis clearly shows that colposcopy and cytology underestimate the histological results in patients with limited visibility due to the presence of a type 3 transformation zone (TZ). Our analysis revealed a significant discrepancy between the colposcopy and cytology results and the histological outcomes. Insufficient colposcopy led to the underdiagnosis of dysplastic lesions in patients with a type 3 TZ and cervical stenosis. In the case of repeated cytological abnormalities and inadequate colposcopy examination, it is crucial to perform a diagnostic conization to exclude high-grade dysplastic changes and cervical carcinoma.
METHODS: We conducted a retrospective analysis of 1,021 conizations performed in tertiary care hospital in Wolfsburg, Germany between 2014 and 2020. Of these surgical procedures, 89 were diagnostic conizations. In our analysis, we defined diagnostic conization as a procedure performed when there is HPV persistence and repeated cytologic abnormalities in combination with a type 3 TZ, and when it is not possible to retrieve a relevant cervical histology sample.
RESULTS: In this period, 8.7% of all conizations were diagnostic excisions. We found histological abnormalities in 48 of 89 patients (53.9%). The histological examination of the excised cone revealed high-grade cervical intraepithelial neoplasia (CIN/HSIL) in 9 patients (10.1%) and CIN 2+ (HSIL) in 23 out of the 89 patients (25.8%). Two cases of early-stage cervical carcinoma (FIGO IA1 and FIGO IA2) were confirmed (2.3%).
CONCLUSION: Patients with cervical stenosis, high-risk HPV persistence and repeated cytological abnormalities are at high risk of undetected high-grade cervical dysplasia. Histologic confirmation must be ensured in this patient consultation and this can be achieved by performing diagnostic excisions.
Etodolac capsules and tablets, USP are members of the pyranocarboxylic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each tablet and capsule contains etodolac for oral administration. Etodolac is a racemic mixture of [+]S and [-]R-enantiomers. Etodolac is a white crystalline compound, insoluble in water but soluble in alcohols, chloroform, dimethyl sulfoxide, and aqueous polyethylene glycol.

The chemical name is (±) 1,8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid. The molecular weight of the base is 287.37. It has a pKa of 4.65 and an n-octanol: water partition coefficient of 11.4 at pH 7.4. The molecular formula for etodolac is C17H21NO3, and it has the following structural formula:

Each Capsule, for oral administration, contains 200 or 300 mg of Etodolac. In addition, each capsule contains the following inactive ingredients: Ammonium Hydroxide USP, Black Iron Oxide USP, Colloidal Silicone Dioxide NF, Erythrosine (200 mg only), Ethyl Alcohol USP, Gelatin, Isopropyl Alcohol USP, Lactose Monohydrate NF, Magnesium Stearate NF, Microcrystalline Cellulose NF, N-Butyl Alcohol USP, Povidone USP, Propylene Glycol USP, Purified Water USP, Shellac, Titanium Dioxide.

Each Tablet, for oral administration, contains 400 mg or 500 mg of Etodolac. In addition, each tablet contains the following inactive ingredients: Hydroxypropyl Methylcellulose USP, Lactose Monohydrate NF, Magnesium Stearate, Microcrystalline Cellulose NF, Polyethylene Glycol, Povidone USP, Sodium Starch Glycolate NF and Titanium Dioxide. Also, each 400 mg tablet contains Iron Oxide Red and Iron Oxide Yellow. Each 500 mg tablet contains D&C Yellow #10 Aluminum Lake, FD&C Blue #1 Aluminum Lake, and FD&C Red #40 Aluminum Lake.
Clofarabine Injection contains clofarabine, a purine nucleoside metabolic inhibitor. The chemical name of clofarabine is 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purin-6-amine. Its molecular formula is C10H11ClFN5O3 with a molecular weight of 303.68 Daltons.

The molecular structure of clofarabine is:

Clofarabine Injection (1 mg per mL) is supplied in a 20 mL single-dose vial. The 20 mL vial contains 20 mg clofarabine formulated in 20 mL unbuffered normal saline (comprised of Water for Injection, USP and Sodium Chloride, USP). The pH range of the solution is 4.5 to 7.5. The solution is sterile, clear and practically colorless, and is preservative-free.
Placebo control gel. Similar to Tendoncel but without platelet derived small molecules and growth factors. 80ul applied once a day for 21 consecutive days.
Mindfulness based stress reduction: 8 week program, including meditation, body-awareness, and yoga practices. Daily assignments and home practices during 50 minutes per day.
PROBLEM TO BE SOLVED: To obtain taxol, which is an anticancer agent effective for leukemia, etc., but little in the contents in plants, in a good yield from Taxus cuspidata var. nana. Hort. ex Rehder as a raw material. SOLUTION: The leaves, duramen or bark of Taxus cuspidata var. nana. Hort. ex Rehder from Miyagi prefecture, Toyama prefecture, etc., is extracted with an alcohol (e.g. methanol), and the concentrated solution of the alcohol extract is extracted with ethyl acetate to obtain the crude extract. The obtained ethyl acetate layer is extracted with an aqueous sodium bicarbonate solution to separate a carboxylic acid fraction. The layer is extracted with a dilute alkaline solution to separate a phenol fraction. The layer is further extracted with a dilute hydrochloric acid solution to separate an alkaloid fraction and a neutral fraction. The neutral fraction is subjected to a silica gel column chromatography having active carbon spread on the upper layer and subsequently eluted with an organic solvent such as benzene to obtain taxol.
The invention provides a 2-aminothiazole pyrimidopyridone compound or pharmaceutically acceptable salt thereof or stereoisomer thereof, and a preparation method and application thereof, and belongs to the field of organic compounds. The invention provides a 2-aminothiazole pyrimidopyridone compound or pharmaceutically acceptable salt thereof or stereoisomer thereof. The compound can inhibit RET activity, and is a novel protein kinase inhibitor which can overcome the drug resistance of the existing RET tyrosine kinase inhibitor and has selectivity and good drug generation property. The compound of the invention can inhibit the growth of various tumor cells, and especially can selectively inhibit RET lung cancer cells. The compound can be used for preparing antitumor drugs and can overcome drug resistance induced by the existing drugs and the like. The compounds of the invention are useful in preventing postoperative recurrence of various tumors, and in further consolidated therapy.
Inductive chemotherapy plus CCRT or operation is an option of organ preservation for patients of hypopharyngeal carcinoma. Many clinical studies have demonstrated that inductive chemotherapy plus CCRT achieved the same prognosis as total laryngectomy, and minimized the damage of normal tissue. TPF is the standard regime of inductive chemotherapy for squamous carcinoma of head and neck. If the primary tumor shrinks obviously (complete remission or \>75% partial remission )after inductive chemotherapy, CCRT is suggested as the definitive therapy, for the tumor is sensitive to chemotherapy. If the primary tumor shrinks a little or progresses after inductive chemotherapy, operation is suggested as the definitive therapy to get a longer survival. This is a prospective, phase II, cohort study. We designate TPF plus Toripalimab as the inductive regime, expecting a higher complete remission rate and longer PFS and OS. And we replace the CCRT with radiation plus Toripalimab to decrease the adverse events of CCRT.
The invention discloses a PEG-MAL modified two-dimensional black phosphorus hybrid nano-drug targeting HER2 positive breast cancer, belonging to the field of nano-drugs. The preparation method comprises the following steps: (1) preparing two-dimensional black phosphorus quantum dots BPQDs with the particle size of 3-7 nm; (2) BP-PEG-MAL-Tmb. The invention selects the novel two-dimensional black phosphorus nano material capable of completely metabolizing as the inorganic nano platform, and has higher drug loading rate and photo-thermal conversion rate. Modification of PEG-MAL can not only improve colloidal stability and biocompatibility of nano-drug, but also effectively enhance capture ability of antigen presenting cells to antigen, and stimulate organism immunoreaction. The modification of Tmb enables the nano-drug to effectively target HER2 positive breast cancer, and further improves the colloidal stability of the nano-drug. The medicine Tmb for resisting HER2 positive breast cancer is organically combined with the two-dimensional black phosphorus for the first time, the targeted photo-thermal immune composite treatment for HER2 positive breast cancer is realized, the design method is simple, the reaction condition is mild, and a new strategy is provided for the accurate treatment of the breast cancer.
PURPOSE:An antibody usable as a diagnosticum for the stomach, obtained by using a specific peptide as an antigen. CONSTITUTION:An animal such as mouse, etc. is immunized against a bonded material of an antigen peptide shown by the formula and a carrier protein (e.g., keyhole limpet hemocyanin, bovine serum albumin, etc.). A lymphocyte of the immunized animal is fused with myeloma to give a hybridoma to produce specifically an antibody, form which a monoclonal antibody is obtained. The prepared immunoglobulin has properties shown by the table I. The antibody against a sarcoma gene product is usable as a diagnosticum for cancers and can possibly be used as a remedy for cancers.
Mechanical ventilation contributes to the morbidity and mortality of patients in intensive care, likely through the exacerbation and dissemination of inflammation. Despite the proximity of the pleural cavity to the lungs and exposure to physical forces, little attention has been paid to its potential as an inflammatory source during ventilation. Here, we investigate the pleural cavity as a novel site of inflammation during ventilator-induced lung injury. Mice were subjected to low or high tidal volume ventilation strategies for up to 3 hours. Ventilation with a high tidal volume significantly increased cytokine and total protein levels in BAL and pleural lavage fluid. In contrast, acid aspiration, explored as an alternative model of injury, only promoted intraalveolar inflammation, with no effect on the pleural space. Resident pleural macrophages demonstrated enhanced activation after injurious ventilation, including upregulated ICAM-1 and IL-1β expression, and the release of extracellular vesicles. In vivo ventilation and in vitro stretch of pleural mesothelial cells promoted ATP secretion, whereas purinergic receptor inhibition substantially attenuated extracellular vesicles and cytokine levels in the pleural space. Finally, labeled protein rapidly translocated from the pleural cavity into the circulation during high tidal volume ventilation, to a significantly greater extent than that of protein translocation from the alveolar space. Overall, we conclude that injurious ventilation induces pleural cavity inflammation mediated through purinergic pathway signaling and likely enhances the dissemination of mediators into the vasculature. This previously unidentified consequence of mechanical ventilation potentially implicates the pleural space as a focus of research and novel avenue for intervention in critical care.
BACKGROUND AND OBJECTIVE: The incidence of intralabyrinthine schwannomas is increasing, and a growing attention is given to the detrimental effects on hearing function. On the contrary, the vestibular profile of intralabyrinthine vestibular schwannomas (VSs) is still not well understood. We aimed to investigate and report the observed relationships between the intralabyrinthine location of the schwannomas and objective and subjective vestibular profile of the patients.
METHODS: Retrospective cohort study of 20 consecutive individuals with sporadic intralabyrinthine schwannomas and grouped according to the intralabyrinthine location of the schwannomas. Vestibular testing consisted of the video head impulse test of all three semicircular canals, the caloric test, cervical and ocular vestibular evoked myogenic potentials, and the dizziness handicap inventory. A nonparametric unpaired t test was performed to compare groups, and Fisher's exact test was used for categorical data.
RESULTS: The median video head impulse test gains (lateral, anterior, posterior) were 0.40, 0.50, and 0.75 for intravestibular schwannomas and 0.93, 1.52, and 0.91 for intracochlear schwannomas ( p = 0.0001, p = 0.009, p = 0.33), respectively. Caloric unilateral weakness had a median of 100% for intravestibular schwannomas and 14% for intracochlear schwannomas ( p = 0.0001). The mean dizziness handicap inventory was 21 for intravestibular schwannomas and 1 for cochlear schwannomas ( p = 0.02). There were no significant differences in vestibular evoked myogenic potentials according to intralabyrinthine location.
CONCLUSION: By both objective and subjective measures, intralabyrinthine schwannomas with an intravestibular component has significantly worse vestibular function than schwannomas with purely cochlear involvement.
Participants randomized to this arm will be provided with food items including entrées, side dishes, salad dressing, baked goods, and desserts prepared with traditional canola oil to incorporate into their usual eating pattern. They will consume one or two food items per day containing a total of 25 g/d of Canola oil.
Phytosterins are extracted from raw materials containing them by a process which comprises steam distillation in a high vacuum and at a high temperature, for example, above 200 DEG  C., followed by a further treatment of the distillate for the isolation of the phytosterins.  The preferred distillation pressure is from 2--20 mms. of mercury.  The preferred further purification treatment of the distillate is fractional crystallization which also effects a separation of the various phytosterins.  This treatment may be followed by a saponification process with alkali and the product extracted with benzene or alcohol.  Raw materials mentioned are alcohol extracts from oil production and the acetic ester or acetone extracts from lecithin purification.  In an example, soya oil is steam distilled in a vacuum of 2--20 mms. of mercury, the distillate dissolved in alcohol, allowed to crystallize, centrifuged and if desired further purified by crystallization. The product so obtained has a phytosterin content of about 25 per cent and may be further purified by a saponification with potash, and crystallization from alcohol.ALSO:Phytosterins are extracted from raw materials containing them by a process which comprises steam distillation in a high vacuum and at a high temperature for example above 200 DEG  C., followed by a further treatment of the distillate for the isolation of the phytosterins.  The prepared distillation pressure is from 2--20 mms. of mercury.  Raw materials mentioned are alcohol extracts from oil production and the acetic ester or acetone extracts from lecithin purification.  In an example soya oil is steam distilled in a vacuum of 2--20 mms. of mercury, the distillate dissolved in alcohol, allowed to crystallize, centrifuged, and if desired further purified by crystallization.  The product so obtained has a phytosterin content of about 25 per cent.
OBJECTIVE: To assess the cost effectiveness of targeting a blood pressure of less than 140/90 mm Hg compared with 160/105 mm Hg.
METHODS: A decision-analytic model was constructed to compare the treatment of chronic hypertension in pregnancy at mild-range blood pressures (140/90 mm Hg) with the treatment of chronic hypertension before 20 weeks of gestation at severe-range blood pressures (160/105 mm Hg) in a theoretical cohort of 180,000 patients with mild chronic hypertension. Probabilities, costs, and utilities were derived from literature and varied in sensitivity analyses. Primary outcomes included incremental cost per quality-adjusted life-year (QALY), cases of preeclampsia, preeclampsia with severe features, severe maternal morbidity (SMM), preterm birth, maternal death, neonatal death, and neurodevelopmental delay. The cost-effectiveness threshold was $100,000 per QALY.
RESULTS: Treating chronic hypertension in a population of 180,000 pregnant persons at mild-range blood pressures, compared with severe-range blood pressures, resulted in 14,177 fewer cases of preeclampsia (43,953 vs 58,130), 11,835 of which were cases of preeclampsia with severe features (40,530 vs 52,365). This led to 817 fewer cases of SMM (4,375 vs 5,192), and 18 fewer cases of maternal death (102 vs 120). Treating at a lower threshold also resulted in 8,078 fewer cases of preterm birth (22,000 vs 30,078), which led to 26 fewer neonatal deaths (276 vs 302) and 157 fewer cases of neurodevelopmental delay (661 vs 818). Overall, treating chronic hypertension at a lower threshold was a dominant strategy that resulted in decreased costs of $600 million and increased effectiveness of 12,852 QALYs.
CONCLUSION: Treating chronic hypertension at a threshold of mild-range blood pressures is a dominant (lower costs, better outcomes) and cost-effective strategy that results in fewer neonatal and maternal deaths compared with the standard treatment of treating at severe range blood pressures.
Spinal block with bupivacaine HCl 7.5 mg/mL. Local infiltration of EXPAREL 266 mg.
Peripheral artery disease is a common condition in patients on chronic dialysis treatment, end-stage kidney failure itself being a risk factor. The most severe stage of peripheral artery disease, critical limb ischemia, causes marked chronic pain and is associated with risk of limb loss. Despite improvements in revascularization procedures, the results of limb salvage procedures among dialysis patients remains poor, and lower extremity amputation is associated with high mortality and grim socio-economic implications. We report on a limb salvage approach that was successfully employed in a 74-year-old woman on hemodialysis suffering from no-option critical limb ischemia complicated by diabetic foot infection, i.e. otherwise a candidate for major amputation. The approach consists in implanting in the wound bed of the affected limb a concentrate of autologous peripheral blood mononuclear cells collected from the peripheral blood of the patient using a selective filtration separation system. The procedure, performed by a vascular surgeon in an outpatient setting and sterile conditions, was repeated three times at intervals of 15 days, and was well tolerated; no adverse safety signals were observed. Complete wound healing was obtained, with successful limb rescue.
PROBLEM TO BE SOLVED: To obtain a periodontal disease-therapeutic material that is suitable for the therapy of such severe periodontal diseases that need regeneration of periodontal tissues and restoration of bite functions by impregnating a specific membrane body with a protein including the residue of hydroxyproline. SOLUTION: The objective therapeutic material for periodontal diseases is prepared by impregnating (B) a membrane body made of a material that is resorptive in vivo with (A) a protein including residual groups of hydroxyproline. As the component A, may be used an eluate from the dental cement, when the dental cement of mammalian teeth is soaked in an aqueous collagenase solution. The concentration of the collagenase in the aqueous solution is preferably 0.1-15%, and more preferably 0.1-5%. The elution of the residual group of hydroxyproline is preferably 0.01-10 wt.%, more preferably 0.1-3.0% based on the whole residues of amino acids. The amount of the impregnated component A is preferably 0.0001-3 mg/cm2.
Patients in the group A received a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) which started on day 21 of preceding cycle at a dose of 0.1 mg/day. On the second day of menstruation HMG was started and this was associated with reduction of triptorelin to 0.05 mg/day. This reduced daily dose was administered until the day hCG was given. Growth hormone co-treatment was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
Obeticholic acid will be administered orally at a dose of 25 mg/day during three weeks to 20 morbidly obese patients awaiting Roux-en-Y gastric bypass and to 20 healthy volunteers. On the days before the first and after the last dose faeces and blood are sampled for the analyses of bile acids and the gut microbiota. On the day after the last dose a push-enteroscopy is performed in conscious sedation for biopsy taking in the jejunum. These procedures are repeated 6 month after surgery in the morbid obese patients. Inclusion criteria are male or female gender, 20-65 years of age and morbid obesity (BMI \>35 kg/m2) eligible for bariatric surgery. Exclusion criteria are liver diseases other that fatty liver disease, other significant morbidity, medications known to interact with OCA, pregnancy, uncertainty about safe and reliable contraception, and problems to understand or adhere to the protocol. The primary objectives of this pharmacodynamic trial are the study of the effect of OCA on the expression of FXR in the jejenum and small intestinal permeability, and on fecal bile acids and gut microbiota. The secondary objectives are the study of the effects of OCA on the genome-wide FXR DNA binding sites (cistromics) with the global gene expression profile (transcriptomics) in human jejunum.
PROBLEM TO BE SOLVED: To obtain an emulsion having excellent storage stability by selecting an emulsion containing a polyorganosiloxane, a sorbitan surfactant and water in a specified ratio and having a specified emulsion particle diameter and a specified mean particle diameter/modal particle diameter ratio. SOLUTION: There is provided an emulsion composition containing 100 pts.wt. polyorganosiloxane, 1-50 pts.wt. sorbitan surfactant, 20-85 pts.wt. water and further containing 1-50 pts.wt. dispersing/thickening agent being a polyoxyethylene alkyl ether and 1-50 pts.wt. polyethylene glycol fatty acid ester and having an emulsion particle diameter of 1-500 μm and a mean particle diameter/modal particle diameter ratio of 0.7-1.3. If necessary, it may further contain a preservative, vaseline, a bactericide, a humectant, etc. The polyogranosiloxane used is desirably a polydimethylsiloxane having a linear siloxane skeleton, containing 800-100,000 siloxane units and terminated with a trimethylsilyl group, a dimethylhydroxysilyl group or the like.